[Therapeutic monoclonal antibodies against multiple myeloma]

Junya Kuroda

Research output: Contribution to journalArticlepeer-review


Multiple myeloma (MM) remains mostly incurable despite the recent progress in the treatment strategy. One of novel fields for anti-MM therapeutic strategy is the development of immunotherapy using monoclonal antibodies (MoAbs) against myeloma-specific antigens. This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38. Both antigens are highly expressed in more than 90% of MM patients, and the clinical trials have shown promising anti-MM effects, especially in combination with immunomodulatory agent lenalidomide. We also discuss the characteristics and the results of clinical trials of other MoAbs, such as tabalumab against B cell activating factor or dacetuzumab against CD40, being developed for MM.

Original languageEnglish
Pages (from-to)119-123
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number1
Publication statusPublished - Jan 1 2015
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of '[Therapeutic monoclonal antibodies against multiple myeloma]'. Together they form a unique fingerprint.

Cite this